Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

FDC drugs are those that contain a combination of two or more active pharmaceutical ingredients in a fixed ratio and are also ...

A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Scientists have found a surprising new way to make certain cancer drugs work dramatically better – by helping them get inside ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic ...

Lilly said its investigational once-daily pill achieved positive topline results in a late-stage study evaluating the safety and efficacy of orforglipron compared with a placebo in adults with type 2 ...